Contrary to MCP-1 and anti-inflammatory TGF-β, we have increased IL-1β (5.2-fold), TF, and P-selectin levels (2-fold) in joined DLBCL and DLBCL-like lymphomas with an aggressive form of development (Figure 1C,D). This evidence concerns the gene CCL2 and lymphoma.